Formation of celecoxib nanoparticles from volatile microemulsions

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 231-238

  Margulis Goshen, Katrin ^a   Kesselman, Ellina ^b   Danino, Dganit ^b   Magdassi, Shlomo ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Celecoxib; Evaporation; Microemulsion; Organic nanoparticles; Poorly soluble drug

Indexed keywords

AMMONIUM GLYCYRRHIZATE; CELECOXIB; NANOPARTICLE; PHOSPHATIDYLCHOLINE; SURFACTANT; UNCLASSIFIED DRUG; WATER;

ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG SOLUBILITY; DRY POWDER; ELECTRIC CONDUCTIVITY; EVAPORATION; FILTRATION; IMAGE ANALYSIS; MICROEMULSION; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 77953357896     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.012     Document Type: Article

References (53)

1. Aranberri I., Beverley K.J., Binks B.P., Clint J.H., Fletcher P.D.L. How do emulsions evaporate?. Langmuir 2002, 18:3471-3475.
2. Archakov, A.I., Guseva, M.K., Uchaikin, V.F., Tikhonova, E.G., Ipatova, O.M., 2007. Medicinal forms of phospholipid preparations and methods for their preparation. International Patent WO/2007/020505.
3. Auman J.T., Church R., Lee S.Y., Watson M.A., Fleshman J.W., Mcleod H.L. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur. J. Cancer 2008, 44:1754-1760.
4. Baboota S., Faiyaz S., Ahuja A., Ali J., Shafiq S., Ahmad S. Development and validation of a stability-indicating HPLC method for analysis of celecoxib (CXB) in bulk drug and microemulsion formulations. Acta Chromatogr. 2007, 18:116-129.
5. Bellare J.R., Davis H.T., Scriven L.E., Talmon Y. Controlled environment vitrification system: an improved sample preparation technique. J. Electron Microsc. Tech. 1988, 10:87-111.
6. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Gordon G.B., Hawk E.T. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355:873-884.
7. Bushrab F.N., Müller R.H. Nanocrystals of poorly soluble drugs for oral administration. J. New Drugs 2003, 5:20-22.
8. Chan A.T., Zauber A.G., Hsu M., Breazna A., Hunter D.J., Rosenstein R.B., Eagle C.J., Hawk E.T., Bertagnolli M.M. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009, 136:2127-2136.
9. Chen J.F., Zhang J.Y., Shen Z.G., Zhong J., Yun J. Preparation and characterization of amorphous cefuroxime axetil drug nanoparticles with novel technology: high-gravity antisolvent precipitation. Ind. Eng. Chem. 2006, 45:8723-8727.
10. Chen X.X., Young T.J., Sarkari M., Williams R.O., Johnston K.P. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 2002, 242:3-14.
11. Clint J.H., Fletcher P.D.I., Todorov I.T. Evaporation rates of water from water-in-oil microemulsions. Phys. Chem. Chem. Phys. 1999, 1:5005-5009.
12. Cui H., Hodgdon T.K., Kaler E.W., Abezgauz L., Danino D., Lubovsky M., Talmon Y., Pochan D.J. Elucidating the assembled structure of amphiphiles in solution via cryogenic transmission electron microscopy. Soft Matter 2007, 3:945-955.
13. Danino D., Bernheim-Groswasser A., Talmon Y. Digital cryogenic transmission electron microscopy: an advanced tool for direct imaging of complex fluids. Colloid Surf. A 2001, 183:113-122.
14. Dannenberg A.J., Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003, 4:431-436.
15. De Gennes P.G., Taupin C. Microemulsions and the flexibility of oil/water interfaces. J. Phys. Chem. 1982, 86:2294-2304.
16. Debuigne F., Jeunieau L., Wiame M., Nagy J.B. Synthesis of organic nanoparticles in different W/O microemulsions. Langmuir 2000, 16:7605-7611.
17. Desgouilles S., Vauthier C., Bazile D., Vacus J., Grossiord J.L., Veillard M., Couvreur P. The design of nanoparticles obtained by solvent evaporation: a comprehensive study. Langmuir 2003, 19:9504-9510.
18. Destree C., Debuigne F., Jeunieau L., Nagy J.B. Mechanism of formation of inorganic and organic nanoparticles from microemulsions. Adv. Colloid. Interface Sci. 2006, 123-126:353-367.
19. Destree C., Ghijsen J., Nagy J.B. Preparation of organic nanoparticles using microemulsions: their potential use in transdermal delivery. Langmuir 2007, 23:1965-1973.
20. Detrembleur C., De Nayer J., Van Den Hecke A. Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial. Osteoarthr. Cartil. 2005, 13:206-210.
21. Dhingra D., Sharma A. Evaluation of antidepressant-like activity of glycyrrhizin in mice. Indian J. Pharamacol. 2005, 37:390-394.
22. Gupta P., Chawla G., Bansal A.K. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility. Mol. Pharm. 2004, 1:406-413.
23. Horn D., Rieger J. Organic nanoparticles in the aqueous phase-theory, experiment, and use. Angew. Chem. Int. Ed. 2001, 40:4331-4361.
24. Hu J.H., Johnston K.P., Williams R.O. Rapid dissolving high potency danazol powders produced by spray freezing into liquid process. Int. J. Pharm. 2004, 271:145-154.
25. Keck C.M., Muller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
26. Kivitz A.J., Espinoza L.R., Sherrer Y.R., Liu-Dumaw M., West C.R. A comparison of the efficacy and safety of celecoxib 200mg and celecoxib 400mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin. Arthritis Rheum. 2007, 37:164-173.
27. Knapp L.F. The solubility of small particles and the stability of colloids. Trans. Faraday Soc. 1921, 17:457-465.
28. Koide M., Ukawa J., Tagaki W., Tamagaki S. Hydrolysis of nonionic ester surfactants facilitated by potassium beta-glycyrrhizinate: implication of catalytic functions played by the carboxyl groups. J. Am. Oil Chem. Soc. 1997, 74:49-54.
29. Lin A.H., Liu Y.M., Huang Y., Sun J.B., Wu Z.F., Zhang M., Ping Q.N. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int. J. Pharm. 2008, 359:247-253.
30. Lu G.W., Hawley M., Smith M., Geiger B.M., Pfund W. Characterization of a novel polymorphic form of celecoxib. J. Pharm. Sci. 2006, 95:305-317.
31. Magdassi, S., Netivi (Donio), H., Margulis-Goshen, K., 2007. Organic nanoparticles obtained from microemulsions by solvent evaporation. International Patent Application Number: PCT/IL2007/001136.
32. Margulis-Goshen K., Magdassi S. Formation of simvastatin nanoparticles from microemulsion. Nanomedicine 2009, 5:274-281.
33. Margulis-Goshen K., Netivi (Donio) H., Major D.T., Gradzielski M., Raviv U., Magdassi S. Formation of organic nanoparticles from volatile microemulsions. J. Colloid Interface Sci. 2010, 342:283-292.
34. Matteucci M.E., Brettmann B.K., Rogers T.L., Elder E.J., Williams R.O., Johnston K.P. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol. Pharm. 2007, 4:782-793.
35. Matteucci M.E., Hotze M.A., Johnston K.P., Williams R.O. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 2006, 22:8951-8959.
36. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
37. Niwa T., Shimabara H., Kondo M., Danjo K. Design of porous microparticles with single-micron size by novel spray freeze-drying technique using four-fluid nozzle. Int. J. Pharm. 2009, 382:88-97.
38. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.
39. Oh H.M., Lee S., Park Y.N., Choi E.J., Choi J.Y., Kim J.A., Kweon J.H., Han W.C., Choi S.C., Han J.K., Son J.K., Lee S.H., Jun C.D. Ammonium glycyrrhizinate protects gastric epithelial cells from hydrogen peroxide-induced cell death. Exp. Biol. Med. (Maywood) 2009, 234:263-277.
40. Paolino D., Lucania G., Mardente D., Alhaique F., Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J. Controlled Release 2005, 106:99-110.
41. Paulson S.K., Vaughn M.B., Jessen S.M., Lawal Y., Gresk C.J., Yan B., Maziasz T.J., Cook C.S., Karim A. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J. Pharmacol. Exp. Ther. 2001, 297:638-645.
42. Perrut A., Jung J., Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes Part I: micronization of neat particles. Int. J. Pharm. 2005, 288:3-10.
43. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
44. Shono Y., Jantratid E., Janssen N., Kesisoglou F., Mao Y., Vertzoni M., Reppas C., Dressman J.B. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur. J. Pharm. Biopharm. 2009, 73:107-114.
45. Spernath A., Aserin A., Ziserman L., Danino D., Garti N. Phosphatidylcholine embedded microemulsions: physical properties and improved Caco-2 cell permeability. J. Controlled Release 2007, 119:279-290.
46. Steippler E., Kopp S., Dressman J.B. Comparison of US pharmacopeia simulated intestinal fluid TS (without pancreatin) and phosphate standard buffer pH 6.8, TS of the International Pharmacopoeia with the respect to their use in in vitro dissolution testing. Dissolut. Technol. 2004, 6-10.
47. Trotta M., Gallarate M., Carlotti M.E., Morel S. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int. J. Pharm. 2003, 254:235-242.
48. Trotta M., Peira E., Carlotti M.E., Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 2004, 270:119-125.
49. Turk M., Hils P., Helfgen B., Schaber K., Martin H.J., Wahl M.A. Micronization of pharmaceutical substances by the rapid expansion of supercritical solutions (RESS): a promising method to improve bioavailability of poorly soluble pharmaceutical agents. J. Supercrit. Fluid. 2002, 22:75-84.
50. Yelland M.J., Nikles C.J., Mcnairn N., Del Mar C.B., Schluter P.J., Brown R.M. Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford) 2007, 46:135-140.
51. Yoshioka H., Fujita T., Goto A. Effect of glycyrrhizin on the phosphatidylcholine water-system ESR and calorimetric study. J. Colloid Interface Sci. 1989, 133:442-446.
52. Zeng C.X., Hu Q. Determination of the polyacid dissociation constants of glycyrrhizic acid. Indian J. Chem. A 2008, 47:71-74.
53. Zhu Z.X., Anacker J.L., Ji S.X., Hoye T.R., Macosko C.W., Prud'homme R.K. Formation of block copolymer-protected nanoparticles via reactive impingement mixing. Langmuir 2007, 23:10499-10504.